Mitochondria are no longer regarded merely as the cell’s “powerhouses.” In recent years, they have emerged as a central focus for understanding the mechanisms underlying cancer development, progression, and therapeutic resistance. Recent studies have highlighted three major areas: intercellular mitochondrial transfer, mitochondrial dynamics reprogramming, and the role of mitochondria in immune evasion and cancer dissemination. **First: Intercellular Mitochondrial Transfer — A Newly Identified Mechanism of Immune Evasion** One of the most notable recent discoveries is that cancer cells can “steal” mitochondria from immune cells through tunneling nanotubes. A study published in *Cell Metabolism* in 2026 demonstrated that this phenomenon enables cancer cells to weaken immune surveillance and subsequently use the acquired mitochondria to meet their metabolic demands when spreading to the lymph nodes. In other words, cancer cells do not merely evade the immune system; they also hijack its metabolic machinery to support their own dissemination. **Second: Mitochondrial Dynamics and Therapeutic Resistance** Mitochondria are not static organelles; rather, they continuously undergo fission and fusion. A review published in *Mini Reviews in Medicinal Chemistry* in 2026 reported that cancer cells exploit increased mitochondrial fission to achieve high metabolic flexibility, allowing them to switch between energy-producing pathways and resist programmed cell death. Conversely, abnormal mitochondrial fusion appears to play a role in maintaining mitochondrial quality under therapeutic stress. These findings make mitochondrial dynamics proteins, such as DRP1 and MFN1/2, promising therapeutic targets. **Third: Mitochondrial DNA (mtDNA) Mutations as Biomarkers** Extensive mtDNA mutations accumulate across many types of cancer, particularly in genes encoding components of respiratory chain complexes I, III, and IV. These mutations may enable cancer cells to reprogram their metabolism and potentially enhance their ability to disseminate. More importantly, circulating cell-free mitochondrial DNA (cf-mtDNA) released into the bloodstream can potentially be detected as a non-invasive tool for assessing tumor stage and the degree of oxidative damage, opening new avenues for early diagnosis and monitoring treatment response. **Fourth: Metabolic Flexibility — Beyond the “Warburg Effect”** The traditional view that cancer metabolism is primarily characterized by anaerobic glycolysis—the Warburg effect—is increasingly considered incomplete. Recent literature demonstrates that oxidative phosphorylation (OXPHOS) remains an important contributor to tumor growth. Cancer cells exhibit remarkable metabolic flexibility, switching between glucose, glutamine, and pyruvate depending on environmental conditions and therapeutic pressures. **Key Sources** This article draws on peer-reviewed reviews published in high-impact journals, including *Cell Metabolism* (2026) on mitochondrial transfer and lymphatic dissemination, the *International Journal of Molecular Sciences* (2025) on mitochondrial dysfunction in cancer, *Biomarker Research* (2026) on mtDNA mutations, and *Nature Reviews Cancer* as a foundational reference for the broader framework. It also incorporates recent bibliometric analyses documenting the increasing volume of scientific publications on cancer-associated mitochondrial transfer since 2016, reaching a peak in 2025. By the Head of the Department, Prof. Dr. Younis Abdul Ridha Al-Khafaji Al-Mustaqbal University the First in Iraq